- Home
- Publications
- Publication Search
- Publication Details
Title
Bispecific T-cell engagers for cancer immunotherapy
Authors
Keywords
-
Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 93, Issue 3, Pages 290-296
Publisher
Wiley
Online
2014-11-04
DOI
10.1038/icb.2014.93
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
- (2014) P. Schlegel et al. HAEMATOLOGICA
- Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
- (2014) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
- (2013) Markus Chmielewski et al. Frontiers in Immunology
- A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
- (2012) Kosuke Yamamoto et al. BIOCHEMICAL JOURNAL
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
- (2012) A. Feldmann et al. JOURNAL OF IMMUNOLOGY
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
- (2012) M. Friedrich et al. MOLECULAR CANCER THERAPEUTICS
- Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells
- (2011) T. Zhang et al. CANCER RESEARCH
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
- (2011) Hitoe Torisu-Itakura et al. JOURNAL OF IMMUNOTHERAPY
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
- (2010) Ines Herrmann et al. PLoS One
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
- (2009) T Osada et al. BRITISH JOURNAL OF CANCER
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
- (2009) Maria Amann et al. JOURNAL OF IMMUNOTHERAPY
- Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
- (2009) Ralf Lutterbuese et al. JOURNAL OF IMMUNOTHERAPY
- Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10
- (2009) J. S. Klein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
- (2008) Juliane Witthauer et al. BREAST CANCER RESEARCH AND TREATMENT
- Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells
- (2008) Karin D. Rodland et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started